News
SNOA
1.100
-0.90%
-0.010
Sonoma Pharmaceuticals Q4 revenue rises 48% on US growth
Reuters · 10h ago
Sonoma Pharmaceuticals GAAP EPS of -$0.33, revenue of $5.56M
Seeking Alpha · 10h ago
Sonoma Pharmaceuticals Q4 EPS $(0.33) Misses $(0.24) Estimate, Sales $5.561M Miss $5.565M Estimate
Benzinga · 10h ago
BRIEF-Sonoma Pharmaceuticals Q4 Net Income USD -600 Thousand
Reuters · 10h ago
Sonoma Pharmaceuticals FY26 net loss narrows to $3.18 million; revenue rises 37% to $19.53 million
PUBT · 10h ago
Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results
Barchart · 15h ago
Weekly Report: what happened at SNOA last week (0608-0612)?
Weekly Report · 1d ago
Weekly Report: what happened at SNOA last week (0601-0605)?
Weekly Report · 06/08 09:20
Weekly Report: what happened at SNOA last week (0525-0529)?
Weekly Report · 06/01 09:21
Weekly Report: what happened at SNOA last week (0518-0522)?
Weekly Report · 05/25 09:22
Weekly Report: what happened at SNOA last week (0511-0515)?
Weekly Report · 05/18 09:22
Weekly Report: what happened at SNOA last week (0504-0508)?
Weekly Report · 05/11 09:21
Sonoma Pharmaceuticals announces special shareholder meeting
PUBT · 05/05 21:19
Weekly Report: what happened at SNOA last week (0427-0501)?
Weekly Report · 05/04 09:20
Sonoma Pharmaceuticals Completes Equity Offering to Raise Capital
TipRanks · 04/30 22:55
Sonoma Pharma prices USD 4 million follow-on stock offering at USD 1.35 per share
PUBT · 04/30 21:57
Sonoma Pharmaceuticals Enters Underwriting Agreement With Dawson James Securities On April 24, 2026; To Issue 2,962,962 Units At $1.35 Per Unit In Public Offering
Benzinga · 04/30 21:36
SONOMA PHARMACEUTICALS INC - TO ISSUE 2,962,962 UNITS AT $1.35 PER UNIT IN PUBLIC OFFERING - SEC FILING
Reuters · 04/30 21:18
What's Going On With Sonoma Pharma Stock Monday?
Benzinga · 04/27 13:54
More
Webull provides a variety of real-time SNOA stock news. You can receive the latest news about Sonoma Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About SNOA
Sonoma Pharmaceuticals, Inc. is a global healthcare company. The Company is engaged in developing and producing stabilized hypochlorous acid (HOCl) products for a range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, podiatry, animal health care and non-toxic disinfectants. Its products are all classified as medical devices and categorized as prescription, over-the-counter (OTC) and office dispense products. It offers both prescription and OTC dermatology products, including Epicyn Facial Cleanser, Levicyn Dermal Spray, Levicyn Gel, Levicyn Spray Gel, Celacyn Scar Management Gel. In the United States, it offers Microcyn wound and skin care both as an OTC and prescription product. Its eyecare products include Acuiycn Eyelid and Eyelash Hygiene, and Ocucyn Eyelid and Eyelash Cleanser. MicrocynAH is an HOCl-based topical product that cleans, debrides and treats a wide spectrum of animal wounds and infections.